# Dan Burgess

> Dan Burgess is a seed investor at Pulmocide backing Biotechnology. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: Pulmocide
- Location: Boston, United States
- Total investments: 3
- Last investment: Apr 2014
- Lead investor: 0%
- Last updated: Aug 2026

Dan Burgess is a seed investor at Pulmocide in Boston focused on Biotechnology and Biopharma. Daniel Burgess joined SV Life Sciences as a Venture Partner in 2014.Prior to joining SV, Mr. Burgess was founder, President and CEO of Rempex Pharmaceuticals, Inc. (SVLS Fund V), an antibiotic company that was sold to the Medicines Company two years after its founding in a transaction valued at up to $475 million. Previously Mr. Burgess wasPresident and CEO of Mpex Pharmaceuticals, Inc. (SVLS Fund IV), a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials before it was acquired by Aptalis, Inc. in 2011. Mr. Burgess has also held senior executive positions at a number of other biotechnology companies and served as a Director and Chairman of the Audit Committee of Santarus, Inc. for 10 years until its acquisition by Salix, Inc. in 2014 for $2.7 billion.Mr. Burgess received an AB in Economics from Stanford University and an MBA from Harvard Business School.

## Contacts

5 contacts available for Dan Burgess: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/dan-burgess?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |
| Medical Device | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series B | 1 | 33% |
| Series D | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PanOptica | Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully.Today, significant progressis being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy. | $45M | Series B | Apr 15, 2014 |  |
| Ocular Therapeutix | Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic andbiocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma. | $23.8M | Series D | Jun 10, 2013 |  |
| Celerion | Celerion, a leader in early clinical research, delivers Applied Translational Medicine.In Applied Translational Medicine, Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinicalpharmacology labeling of new medicines.The name Celerion is derived from the Latin celeritas meaning swiftness and speed. Our name reflects our founding principle – to help our clients get their products to the market faster.Celerion’s focus is on the implementation of innovative strategies to generate key data very early to enable go/no-go decisions in drug development. With a large clinical capacity of more than 600 beds (24 in-hospital), efficient bioanalytical laboratories and experienced scientific staff, Celerion offers one of the most experienced clinical pharmacology research networks in the industry. |  | Seed | Apr 06, 2010 |  |

3 of 3 investments shown.

## Co-investors
- [Ascension Ventures](https://shizune.co/investors/profile/ascension-ventures) — VC Fund, 1 deal together
- [Baxter International](https://shizune.co/investors/profile/baxter-international) — VC Fund, 1 deal together
- [Novo Ventures](https://shizune.co/investors/profile/novo-ventures) — VC Fund, 1 deal together
- [Polaris Venture Capital](https://shizune.co/investors/profile/polaris-venture-capital) — VC Fund, 1 deal together
- Sparta Group — VC Fund, 1 deal together
- [Sparta Group](https://shizune.co/investors/profile/sparta-group-llc) — VC Fund, 1 deal together

## About Pulmocide

VC Fund · London, United Kingdom

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

4 contacts available at Pulmocide.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Burgess | Chairman and Chief Executive Officer | — |
| Jeanne Bolger | Member Board Of Directors | https://shizune.co/investors/profile/jeanne-bolger |
| Jennifer Cayer | Chief Business Officer | — |
| Pete Strong | CSO | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Dan Burgess invest in?

Dan Burgess invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Seed and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Dan Burgess?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Dan Burgess last invest?

The most recent investment recorded for Dan Burgess closed in Apr 2014. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co